Analysts Expect DexCom, Inc. (NASDAQ:DXCM) Will Announce Earnings of $0.85 Per Share

Equities analysts expect DexCom, Inc. (NASDAQ:DXCM) to announce earnings of $0.85 per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have made estimates for DexCom’s earnings. The highest EPS estimate is $0.93 and the lowest is $0.71. DexCom reported earnings of $0.91 per share in the same quarter last year, which suggests a negative year over year growth rate of 6.6%. The company is expected to issue its next earnings report on Thursday, February 10th.

On average, analysts expect that DexCom will report full year earnings of $2.79 per share for the current fiscal year, with EPS estimates ranging from $2.43 to $2.91. For the next fiscal year, analysts anticipate that the company will report earnings of $3.45 per share, with EPS estimates ranging from $2.56 to $4.08. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover DexCom.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 28th. The medical device company reported $0.89 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.27. The firm had revenue of $650.20 million during the quarter, compared to analyst estimates of $617.07 million. DexCom had a net margin of 22.82% and a return on equity of 14.65%. DexCom’s revenue was up 29.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.94 EPS.

A number of research analysts have commented on the company. Guggenheim lowered DexCom from a “buy” rating to a “neutral” rating in a research report on Monday, October 18th. Stephens lifted their price target on DexCom from $468.00 to $546.00 and gave the stock an “overweight” rating in a research report on Friday, July 30th. SVB Leerink lifted their price target on shares of DexCom from $500.00 to $715.00 and gave the company an “outperform” rating in a research note on Friday, October 29th. Morgan Stanley lifted their price target on shares of DexCom from $510.00 to $576.00 and gave the stock an “equal weight” rating in a report on Friday, October 29th. Finally, Raymond James upped their price objective on shares of DexCom from $515.00 to $618.00 and gave the stock an “outperform” rating in a research report on Monday, November 1st. Three equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $574.44.

In other DexCom news, EVP Chad Patterson sold 141 shares of the firm’s stock in a transaction dated Wednesday, October 13th. The stock was sold at an average price of $545.54, for a total transaction of $76,921.14. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Steven Robert Pacelli sold 6,743 shares of the firm’s stock in a transaction dated Thursday, September 23rd. The shares were sold at an average price of $573.34, for a total value of $3,866,031.62. The disclosure for this sale can be found here. Insiders sold a total of 38,862 shares of company stock worth $21,958,010 in the last 90 days. 0.52% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DXCM. Jefferies Group LLC boosted its position in shares of DexCom by 7.0% during the second quarter. Jefferies Group LLC now owns 10,700 shares of the medical device company’s stock valued at $4,569,000 after buying an additional 700 shares during the period. Tiedemann Advisors LLC purchased a new position in shares of DexCom during the second quarter valued at approximately $1,377,000. Oppenheimer & Co. Inc. raised its stake in shares of DexCom by 7.4% during the second quarter. Oppenheimer & Co. Inc. now owns 10,341 shares of the medical device company’s stock valued at $4,416,000 after acquiring an additional 712 shares in the last quarter. Nuveen Asset Management LLC raised its stake in shares of DexCom by 42.1% during the second quarter. Nuveen Asset Management LLC now owns 1,830,424 shares of the medical device company’s stock valued at $781,591,000 after acquiring an additional 542,070 shares in the last quarter. Finally, Blair William & Co. IL raised its stake in DexCom by 1.7% in the second quarter. Blair William & Co. IL now owns 1,206,782 shares of the medical device company’s stock worth $515,296,000 after buying an additional 20,119 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Shares of DXCM stock traded up $8.58 on Thursday, hitting $598.58. 729,061 shares of the company’s stock were exchanged, compared to its average volume of 720,204. The company has a 50 day moving average of $582.00 and a 200 day moving average of $494.32. DexCom has a 12 month low of $311.01 and a 12 month high of $659.45. The stock has a market cap of $58.02 billion, a P/E ratio of 114.45 and a beta of 0.73. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.98 and a quick ratio of 4.50.

DexCom Company Profile

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.

Read More: Are sell-side analysts objective?

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.